American Gene Technologies

Executive Summary

American Gene Technologies (AGT) is a privately held gene and cell therapy company based in Rockville, Maryland, specializing in a proprietary lentiviral platform with broad therapeutic applications. The company's lead program targets a functional cure for HIV, which was initially expected to enter clinical trials in 2018 and is now in Phase 1 development. AGT has also developed a patented immuno-oncology approach aimed at attacking a variety of epithelial cancers. Despite limited public updates, AGT's lentiviral platform offers potential advantages in delivering therapeutic genes to target cells, supporting its pipeline in infectious disease and oncology. The company remains in early clinical stages, with no disclosed financials or valuation, and faces typical early-stage risks including regulatory, manufacturing, and clinical validation challenges. Its success hinges on advancing its HIV program through the clinic and demonstrating platform versatility in other indications.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for HIV gene therapy40% success
• Q4 2026Presentation of preclinical data for immuno-oncology program60% success
• Q4 2026Announcement of strategic partnership or financing round50% success